Read more

March 15, 2021
1 min read
Save

Six important updates for Colorectal Cancer Awareness Month

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Colorectal Cancer Awareness Month is observed in March.

The observance is intended to increase awareness about the prevalence of the disease, its symptoms, and the key role screening plays in reducing colorectal cancer incidence and mortality.

Dark blue ribbon for colon - colorectal cancer awareness.
Source: Adobe Stock.

Colorectal cancer is the second leading cause of cancer mortality in the United States.

An estimated 104,270 people in the U.S. will be diagnosed with the malignancy this year, and 45,230 will die of the disease, according to American Cancer Society.

In conjunction with Colorectal Cancer Awareness Month, Healio and HemOnc Today present the following important updates in treatment.

  • Long-term, regular use of aspirin before diagnosis appeared associated with lower colorectal cancer-specific mortality, according to results of an observational study published in Journal of the National Cancer Institute. Read more.
  • The combination of panitumumab (Vectibix, Amgen), ipilimumab (Yervoy, Bristol Myers Squibb) and nivolumab (Opdivo, Bristol Myers Squibb) induced responses among patients with metastatic colorectal cancer, according to phase 2 study results. Read more.
  • A planned study will evaluate CYAD-101 (Celyad Oncology) — an investigational non-gene edited allogeneic CAR T-cell therapy — in combination with the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) for treatment of late-stage metastatic colorectal cancer. Read more.
  • Circulating tumor DNA analysis outperformed an established biomarker in predicting risk for colorectal cancer recurrence after surgery. Read more.
  • Treatment disparities mediated about one-third of OS differences observed between white and Black patients with stage IV colorectal cancer. Read more.
  • Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer. Read more.